Profile data is unavailable for this security.
About the company
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
- Revenue in USD (TTM)0.00
- Net income in USD-129.47m
- Incorporated2014
- Employees104.00
- LocationOric Pharmaceuticals Inc240 E. Grand Ave, 2nd FloorSOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://oricpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Taysha Gene Therapies Inc | 6.31m | -99.93m | 1.24bn | 73.00 | -- | 5.67 | -- | 196.65 | -0.3328 | -0.3328 | 0.0212 | 0.7995 | 0.0254 | -- | -- | 86,438.36 | -40.23 | -70.59 | -45.55 | -88.39 | -- | -- | -1,583.66 | -2,287.96 | -- | -- | 0.1899 | -- | -46.07 | -- | 19.96 | -- | -- | -- |
| Azenta Inc | 594.95m | 28.69m | 1.24bn | 3.00k | 43.15 | 0.724 | 14.54 | 2.09 | 0.6252 | -1.26 | 12.98 | 37.26 | 0.2891 | 4.03 | 4.00 | 198,317.70 | 1.39 | -0.3901 | 1.57 | -0.4328 | 44.59 | 45.32 | 4.82 | -1.73 | 2.61 | -- | 0.00 | -- | 3.55 | 8.85 | 200.38 | -- | -3.24 | -- |
| Alvotech SA | 573.35m | 69.50m | 1.24bn | 1.01k | 19.07 | -- | 11.83 | 2.17 | 0.2093 | 0.2093 | 1.93 | -0.5671 | 0.434 | 1.53 | 4.30 | 567,111.80 | 5.26 | -- | 6.38 | -- | 55.59 | -- | 12.12 | -201.24 | 0.7376 | 2.57 | 1.16 | -- | 426.84 | 42.86 | 57.98 | -- | 47.91 | -- |
| MoonLake Immunotherapeutics | 0.00 | -227.32m | 1.26bn | 130.00 | -- | 4.10 | -- | -- | -3.52 | -3.52 | 0.00 | 4.27 | 0.00 | -- | -- | 0.00 | -51.05 | -- | -55.64 | -- | -- | -- | -- | -- | -- | -33.78 | 0.1957 | -- | -- | -- | -91.13 | -- | -- | -- |
| Capricor Therapeutics Inc | 11.13m | -81.99m | 1.28bn | 160.00 | -- | 15.22 | -- | 114.72 | -1.80 | -1.80 | 0.2451 | 1.83 | 0.1015 | -- | 47.48 | 69,565.69 | -74.74 | -45.52 | -96.03 | -61.91 | -- | -- | -736.62 | -248.15 | -- | -- | 0.0387 | -- | -11.55 | 85.83 | -81.57 | -- | -- | -- |
| Monte Rosa Therapeutics Inc | 181.54m | 20.95m | 1.29bn | 147.00 | 70.84 | 4.46 | 44.21 | 7.13 | 0.2506 | 0.2506 | 2.20 | 3.98 | 0.4685 | -- | 65.30 | 1,354,761.00 | 5.41 | -33.14 | 6.24 | -39.19 | -- | -- | 11.54 | -563.84 | -- | -- | 0.00 | -- | -- | -- | 46.29 | -- | 23.56 | -- |
| Septerna Inc | 22.05m | -58.81m | 1.30bn | 75.00 | -- | 3.33 | -- | 58.94 | -1.51 | -1.51 | 0.5304 | 8.71 | 0.0565 | -- | 4.98 | 293,933.30 | -15.06 | -- | -16.99 | -- | -- | -- | -266.77 | -- | -- | -- | 0.00 | -- | 611.92 | -- | -12,762.79 | -- | -- | -- |
| AtaiBeckley Inc | 3.02m | -154.19m | 1.32bn | 54.00 | -- | 5.46 | -- | 436.12 | -0.8136 | -0.8136 | 0.0161 | 0.6644 | 0.0138 | -- | 0.3354 | 55,981.48 | -70.56 | -45.69 | -77.07 | -50.03 | -- | -- | -5,104.20 | -2,658.81 | -- | -- | 0.00 | -- | -1.91 | -- | -271.09 | -- | 37.97 | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -129.47m | 1.35bn | 104.00 | -- | 3.45 | -- | -- | -1.51 | -1.51 | 0.00 | 3.90 | 0.00 | -- | -- | 0.00 | -37.91 | -36.88 | -40.60 | -39.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1.27 | -- | 1.31 | -- |
| Rapport Therapeutics Inc | 0.00 | -97.70m | 1.38bn | 69.00 | -- | 2.70 | -- | -- | -2.71 | -2.71 | 0.00 | 10.74 | 0.00 | -- | -- | 0.00 | -22.55 | -- | -23.12 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -125.11 | -- | -- | -- |
| Zenas Biopharma Inc | 15.00m | -189.90m | 1.41bn | 130.00 | -- | 5.66 | -- | 94.30 | -12.67 | -12.67 | 0.4565 | 4.65 | 0.0414 | -- | -- | 115,384.60 | -52.35 | -- | -60.38 | -- | -- | -- | -1,265.99 | -- | -- | -116.56 | 0.2709 | -- | -90.00 | -- | -322.87 | -- | -- | -- |
| Vir Biotechnology Inc | 68.56m | -437.99m | 1.43bn | 367.00 | -- | 1.66 | -- | 20.83 | -3.16 | -3.16 | 0.4949 | 5.49 | 0.0571 | -- | -- | 186,801.10 | -36.47 | -5.87 | -40.01 | -6.81 | 99.96 | 92.66 | -638.87 | -18.05 | -- | -- | 0.00 | -- | -7.61 | -2.14 | 16.09 | -- | -5.90 | -- |
| MBX Biosciences Inc | 0.00 | -80.50m | 1.46bn | 43.00 | -- | 3.76 | -- | -- | -3.39 | -3.39 | 0.00 | 8.67 | 0.00 | -- | -- | 0.00 | -23.59 | -- | -24.41 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -90.16 | -- | -- | -- |
Data as of Mar 02 2026. Currency figures normalised to Oric Pharmaceuticals Inc's reporting currency: US Dollar USD
43.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| EcoR1 Capital, LLCas of 31 Dec 2025 | 6.73m | 6.91% |
| Viking Global Investors LPas of 31 Dec 2025 | 6.57m | 6.75% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 5.08m | 5.22% |
| Alkeon Capital Management LLCas of 31 Dec 2025 | 4.50m | 4.63% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 4.26m | 4.37% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.97m | 4.07% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Dec 2025 | 3.22m | 3.30% |
| Point72 Asset Management LPas of 31 Dec 2025 | 2.92m | 3.00% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 2.48m | 2.55% |
| Paradigm BioCapital Advisors LPas of 31 Dec 2025 | 2.40m | 2.47% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
